ImmunityBio Q3 revenue jumps on ANKTIVA demand

Reuters
2025.11.05 08:48
portai
I'm PortAI, I can summarize articles.

ImmunityBio reported a 434% year-over-year increase in Q3 2025 product revenue, driven by strong demand for ANKTIVA. The company's cash position rose to $257.8 million as of September 30, 2025. However, it did not provide specific financial guidance for future quarters. R&D expenses increased to $51.2 million. The average analyst rating is "buy," with a median 12-month price target of $8.00, significantly above its recent closing price of $2.08.

Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.